

Bioinformatics In Biomarker Discovery

Dr Adrian Carr Bioinformatics Team Leader

Fios Genomics

- University of Edinburgh spin-out
- Formed in 2008
- Based in Edinburgh's BioQuarter
- Provides bioinformatic data analysis services to pharma, biotech, CROs and academia
- Over 500 contracts completed.







'Omics Analysis

Advances in sequencing & array technologies has opened several new avenues for drug development/process improvement



Issues:

- Volume of data
- Complexity of outputs
- Diverse and large number of data/knowledge base systems
- Current "gold standard" for genomics analysis
- What technology to use where?
- Interpretation issues



How Can Fios Help?

- Experimental design
- Technology/platform selection
- Data analysis platform independent
- Integration of 'omics data with virtually any other quantitative outputs
- Use of proprietary modular work flows to simplify complex projects.







What we do



Data QC and normalisation





What we do



Case studies





CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY

Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts

Immune Phenotype Shifts Katherine E. Hutchinson¹, Susan E. Yost², Ching-Wei Chang³, Radia Marie Johnson⁴, Adrian R. Carr⁵, Paul R. McAdam⁵, Daniel L. Halligan⁵, Chun-Chieh Chang³, Daniel Schmolze⁶, Jackson Liang¹, and Yuan Yuan²





Background and experimental design

- Emerging data suggest immune checkpoint inhibitors have reduced efficacy in heavily pretreated triple-negative breast cancer (TNBC)
- Paired primary and metastatic samples collected from 43 patients with recurrent TNBC
- Targeted exome sequencing and whole transcriptome sequencing performed
- Somatic mutation profiles, tumor mutation burden (TMB), molecular subtypes, immune-related gene signatures, stromal TILs, recurrence-free survival (RFS) and overall survival (OS) analysed



Genomic landscape of recurrent TNBCs

- 34 TNBC pairs (68 samples) were sequenced using FoundationOne targeted NGS assay
- The most common mutations were in: TP53, MYC, PIK3CA, PTEN and RB1
- On average, 50% of mutations were shared between pairs, 16% unique to primary samples and 34% unique to metastatic
- No consistent mutational shifts observed between primary and metastatic
- No significant copy number or tumor mutation burden (TMB) changes observed between primary and metastatic



Concordance of oncogenic variants between primary and metastatic samples.





Tumor infiltrating lymphocytes (TILs) and survival







Differential Gene Expression Analysis

- RNA-seq performed on 35 P/M pairs of specimens
- Metastatic vs. Primary comparison identified 1,001 genes (FDR < 0.05)
- Immune-related KEGG pathways were enriched in genes that were downregulated in metastatic





KEGG pathway enrichment in metastatic vs. primary TNBCs

Enriched KEGG pathways associated with



Enriched KEGG pathways associated with genes downregulated in metastatic vs. primary TNBCs



5

Molecular subtypes shifts between primary and metastatic TNBC pairs



Lehmann-Pietenpol subtypes

Burstein subtypes



Immunomodulatory Gene Signatures

- Composite expression score calculated for 4 published immunological activity gene signatures
- IFNg, T-cell inflamed, Th1 responseactivating and Immune-activating
- Composite scores compared: metastatic
 vs primary
- All four were significantly lower (P < 0.05) in metastatic tumors



Immunomodulatory Gene Signatures





Cell Type Deconvolution Analysis

- Cell type proportions estimated from gene expression data
- Average cell type proportions compared: metastatic vs primary
- Significant decrease of B-cell, CD4+ naïve T-cell, CD8+ T-cell and cancerassociated fibroblast subtypes
- Significant increase of endothelial cell, macrophage, and M1 macrophage subtypes





Conclusions

- Few mutational shifts, but largely consistent transcriptomic shifts in longitudinally paired TNBCs.
- Stromal tumor infiltrating lymphocytes significantly decreased in metastatic samples
- Transcriptomic analysis revealed significantly reduced immune-activating gene expression signatures in recurrent TNBCs
- Data may explain the observed lack of efficacy of immune checkpoint inhibitors (ICI) in heavily pretreated TNBCs







Example – Mariathasan et al.

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Sanjeev Mariathasan¹*, Shannon J. Turley¹*, Dorothee Nickles¹*, Alessandra Castiglioni¹, Kobe Yuen¹, Yulei Wang¹, Edward E. Kadel III¹, Hartmut Koeppen¹, Jillian L. Astarita¹, Rafael Cubas¹, Suchit Jhunjhunwala¹, Romain Banchereau¹, Yagai Yang¹, Yinghui Guan¹, Cecile Chalouni¹, James Ziai¹, Yasin Şenbabaoğlu¹, Stephen Santoro¹, Daniel Sheinson¹, Jeffrey Hung¹, Jennifer M. Giltnane¹, Andrew K. Pierce¹, Kathryn Mesh¹, Steve Lianoglou¹, Johannes Riegler¹, Richard A. D. Carano¹, Pontus Eriksson², Mattias Hoglund², Loan Somarriba³, Daniel L. Halligan³, Michiel van der Heijden⁴, Yohann Loriot⁵, Jonathan E. Rosenberg⁶, Lawrence Fong⁷, Ira Mellman¹, Daniel S. Chen¹, Marjorie Green¹, Christina Derleth¹, Gregg D. Fine¹, Priti S. Hegde¹, Richard Bourgon¹ & Thomas Powles⁸

Nature 554, 544-548 (22 February 2018)



Machine learning

- Survival prediction in mesothelioma using Lasso regression
- Identification of a composite signature (combination of features) that can predict OS



Number of markers



Single-cell RNAseq

- Clustering and annotation of cell types in hematopoietic and tissues sample.
- Celltype specific treatment response



GENOMICS

Flow cytometry

- Longitudinal linear mixed-effect models of lymphocyte subpopulations across treatment groups
- Identifying cell subtypes that change over time & treatment



Sorrentino et al, #1671P, ESMO 2018.



Publications

Full list of publications at https://www.fiosgenomics.com/publications/



Home About Us Our Services Resources Blog Contact Us

Search ...

- - in f

The quality of the work produced by Fios Genomics and its staff and founders has been recognised and published also in other peer-reviewed journals:

- Axel W. Wiberg; Daniel L. Halligan; Rob W. Ness; Anamaria Necsulea; Henrik Kaessmann; Peter D. Keightley. Assessing Recent Selection and Functionality at Long Non-Coding RNA Loci in the Mouse Genome R. Genome Biology and Evolution (2015), Link
- Dickinson P., Smith C.L., Forster T., Craigon M., Ross A.J., Khondoker M.R., Ivens A., Lynn D.J., Orme J., Jackson A., Lacaze P., Flanagan K.L., Stenson B.J., Ghazal P. Whole blood gene expression profiling of neonates with confirmed bacterial sepsis. Genomics Data 3, 41-48 (2015). Link
- Keightley P.D., Ness R.W., Halligan D.L., Haddrill P.R. Estimation of the spontaneous mutation rate per nucleotide site in a Drosophila melanogaster full-sib family. Genetics 196, 313-320 (2014). Link
- Kousathanas A., Halligan D.L., Keightley P.D. Faster-X Adaptive Protein Evolution in House Mice. Genetics, 196, 1131-1143 (2014). Link
- Halligan D.L., Kousathanas A., Ness R.W., Harr B., Eory L., Keane T.M., Adams D.J., Keightley P.D. Contributions of Protein-Coding and Regulatory Change to Adaptive Molecular Evolution in Murid Rodents. PLoS Genetics 9(12) (2013). Link
- Kelleher J., Ness R.W., Halligan D.L. Processing genome scale tabular data with wormtable. BMC Bioinformatics, 14, 356 (2013). Link .
- Mabott N.A., Baillie J.K., Brown H., Freeman T.C., Hume D.A. An expression atlas of human primary cells: inference of gene function from coexpression networks. BMC Genomics 14, 632 (2013), Link
- Wilkens J., Male V., Ghazal P., Forster T., Gibsob D.A., Williams A.R., Brito-Mutunayagam S.L., Craigon M., Lourenco P., Cameron I.T., Chwalisz K., Moffett A., Critchley H.O. Uterine NK Cells Regulate Endometrial Bleeding in Women and are Suppressed by the Progesterone Receptor Modulator Asoprisnil. J. Immunology Aug (2) (2013). Link





